Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0801
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2634
    +0.0012 (+0.09%)
     
  • USD/JPY

    151.2170
    -0.1550 (-0.10%)
     
  • Bitcoin USD

    70,152.45
    -368.76 (-0.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

AstraZeneca drug selumetinib fails in uveal melanoma trial

LONDON, July 22 (Reuters) - AstraZeneca's much anticipated cancer drug pipeline suffered a blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for uveal melanoma.

The drugmaker said the setback would not affect other studies using the drug. Selumetinib is being investigated primarily as a treatment for advanced non-small cell lung cancer.

(Reporting by Ben Hirschler, editing; by Louise Heavens)

Advertisement